Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention is a research paper published in Clinical Infectious Diseases (2024). On theSindex it has a DataRank of 0.372. It has been cited 6 times, with 4 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.292
From this paper's citation signal
Citation Network Contribution
0.0802
From 1 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 4 citers.
National Institutes of Health
Grant: AI068634
National Institutes of Health
Grant: AI068636
National Institutes of Health
Grant: AI106701
National Institutes of Health
Grant: K23 AI134307
NIAID NIH HHS
Grant: UM1 AI069432
NIAID NIH HHS
Grant: UM1 AI069456
NIAID NIH HHS
Grant: UM1 AI106701
NIAID NIH HHS
Grant: UM1 AI069436
NIAID NIH HHS
Grant: UM1 AI068634
NIAID NIH HHS
Grant: UM1 AI068636
NIAID NIH HHS
Grant: UM1 AI069496
National Institute of Allergy and Infectious Diseases
FWCI
1.82
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals